Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
(WorldNews Norway)

Oslo, Norway, 11 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the treatment of melanoma and mesothelioma have successfully passed their respective first, planned, independent safety reviews. These are the first studies to investigate ONCOS-102 in combination with other drugs. ......